JP5649825B2
(en)
|
2007-01-31 |
2015-01-07 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Stabilized p53 peptides and methods of use thereof
|
JP5631201B2
(en)
|
2007-03-28 |
2014-11-26 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Stitched polypeptide
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
RU2016111360A
(en)
|
2010-08-13 |
2018-11-27 |
Эйлерон Терапьютикс, Инк. |
PEPTIDOMIMETIC MACROCYCLES
|
US9096642B2
(en)
|
2011-06-08 |
2015-08-04 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
EP3812387A1
(en)
|
2011-07-21 |
2021-04-28 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
CN102286092B
(en)
*
|
2011-09-14 |
2014-01-01 |
深圳翰宇药业股份有限公司 |
Solid-phase synthesis method of liraglutide
|
US11951157B2
(en)
|
2011-10-11 |
2024-04-09 |
Universitat Zurich |
Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
|
US20150017121A1
(en)
|
2011-10-11 |
2015-01-15 |
Universitat Zurich |
Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
|
KR20140100937A
(en)
|
2011-10-18 |
2014-08-18 |
에일러론 테라퓨틱스 인코포레이티드 |
Peptidomimetic macrocycles
|
CN107216380A
(en)
|
2012-02-15 |
2017-09-29 |
爱勒让治疗公司 |
Peptidomimetic macrocyclic compound
|
JP6450192B2
(en)
|
2012-02-15 |
2019-01-09 |
エイルロン セラピューティクス,インコーポレイテッド |
Triazole-bridged and thioether-bridged peptidomimetic macrocycles
|
EP2822957A1
(en)
|
2012-03-07 |
2015-01-14 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
JP5976004B2
(en)
*
|
2012-03-09 |
2016-08-23 |
森永乳業株式会社 |
Dipeptidyl peptidase-IV inhibitor
|
KR20140142736A
(en)
*
|
2012-03-29 |
2014-12-12 |
오리진 디스커버리 테크놀로지스 리미티드 |
Immunomodulating cyclic compounds from the bc loop of human pd1
|
DK2861595T5
(en)
|
2012-06-13 |
2018-01-15 |
Incyte Holdings Corp |
Substituted tricyclic compounds as FGFR inhibitors
|
EA201590451A1
(en)
|
2012-08-30 |
2016-05-31 |
Эмджен Инк. |
METHOD OF TREATING MELANOMA WITH THE USE OF VIRUS HERPES VIRUS AND INHIBITOR IMMUNE CONTROL POINT
|
JP6526563B2
(en)
|
2012-11-01 |
2019-06-05 |
エイルロン セラピューティクス,インコーポレイテッド |
Disubstituted amino acids and methods for their preparation and use
|
PT2928474T
(en)
|
2012-12-07 |
2019-01-30 |
Chemocentryx Inc |
Diazole lactams
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
MX367878B
(en)
|
2013-04-19 |
2019-09-10 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors.
|
TWI676636B
(en)
|
2013-07-12 |
2019-11-11 |
Vlp醫療股份有限公司 |
Virus like particle comprising pd-1 antigen or pd-1 ligand antigen
|
CN105452296B
(en)
|
2013-08-01 |
2020-09-25 |
戊瑞治疗有限公司 |
Afucosylated anti-FGFR 2IIIB antibodies
|
PT3041828T
(en)
|
2013-09-06 |
2018-10-09 |
Aurigene Discovery Tech Ltd |
1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
|
PT3363790T
(en)
|
2013-09-06 |
2020-05-06 |
Aurigene Discovery Tech Ltd |
1,2,4-oxadiazole derivatives as immunomodulators
|
KR20160075506A
(en)
|
2013-09-06 |
2016-06-29 |
오리진 디스커버리 테크놀로지스 리미티드 |
Cyclic peptidomimetic compounds as immunomodulators
|
WO2015036927A1
(en)
*
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
BR112016005816A2
(en)
|
2013-09-20 |
2017-09-19 |
Bristol Myers Squibb Co |
COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS
|
WO2015044900A1
(en)
*
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
CA3185195A1
(en)
|
2013-12-20 |
2015-06-25 |
Intervet International B.V. |
Antibodies against canine pd-1
|
HUE047385T2
(en)
|
2014-06-06 |
2020-04-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
US10385101B2
(en)
|
2014-08-08 |
2019-08-20 |
Vlp Therapeutics, Llc |
Virus like particle comprising modified envelope protein E3
|
US10538555B2
(en)
*
|
2014-09-11 |
2020-01-21 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
EP3191589A4
(en)
|
2014-09-11 |
2018-05-09 |
VLP Therapeutics, LLC |
Flavivirus virus like particle
|
CA2961258A1
(en)
|
2014-09-24 |
2016-03-31 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
US10905739B2
(en)
|
2014-09-24 |
2021-02-02 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and formulations thereof
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
PL3220927T3
(en)
|
2014-11-20 |
2022-05-02 |
Promega Corporation |
Systems and methods for assessing modulators of immune checkpoints
|
EA038349B1
(en)
|
2014-11-21 |
2021-08-12 |
Бристол-Маерс Сквибб Компани |
Antibodies comprising modified heavy chain constant regions
|
LT3221363T
(en)
|
2014-11-21 |
2020-08-10 |
Bristol-Myers Squibb Company |
Antibodies against cd73 and uses thereof
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
EP3234114B9
(en)
|
2014-12-18 |
2023-06-14 |
Amgen Inc. |
Stable frozen herpes simplex virus formulation
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
BR112017013385A2
(en)
|
2014-12-23 |
2018-02-06 |
Bristol-Myers Squibb Company |
antibodies to tigit
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
EP3259269B9
(en)
|
2015-02-20 |
2020-03-04 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
MA41551A
(en)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
|
NZ734650A
(en)
|
2015-03-10 |
2023-07-28 |
Aurigene Oncology Ltd |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
MX2017011617A
(en)
*
|
2015-03-10 |
2018-03-23 |
Aurigene Discovery Tech Ltd |
Therapeutic cyclic compounds as immunomodulators.
|
SG11201706900YA
(en)
*
|
2015-03-10 |
2017-09-28 |
Aurigene Discovery Tech Ltd |
1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2016154058A1
(en)
|
2015-03-20 |
2016-09-29 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
CN104761633B
(en)
*
|
2015-03-25 |
2018-11-27 |
新乡学院 |
Block polypeptide and its application of pig PD-1/PD-L1 access
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
EA035412B1
(en)
|
2015-05-29 |
2020-06-10 |
Бристол-Майерс Сквибб Компани |
Antibodies against ox40 and uses thereof
|
UY36757A
(en)
|
2015-06-29 |
2016-12-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
MONOCLONAL ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY
|
EA201890199A1
(en)
|
2015-07-02 |
2018-06-29 |
Селджин Корпорейшн |
COMBINED THERAPY FOR THE TREATMENT OF HEMOBLASTOSIS AND SOLID TUMORS
|
CN111375066B
(en)
|
2015-07-16 |
2023-04-25 |
百欧肯治疗有限公司 |
Compositions and methods for treating cancer
|
CN116059219A
(en)
|
2015-07-16 |
2023-05-05 |
比奥克斯塞尔医疗股份有限公司 |
Novel method for treating cancer using immunomodulation
|
WO2017032867A1
(en)
|
2015-08-27 |
2017-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a lung cancer
|
WO2017044633A1
(en)
|
2015-09-10 |
2017-03-16 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles as modulators of mcl-1
|
MA44909A
(en)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
KR20180068990A
(en)
|
2015-10-01 |
2018-06-22 |
포텐자 테라퓨틱스, 인코포레이티드 |
Anti-TIGIT antibody-binding proteins and methods for their use
|
EP3355875B1
(en)
|
2015-10-01 |
2021-09-29 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
CA3005855A1
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
MX2018006181A
(en)
*
|
2015-11-23 |
2018-09-24 |
Five Prime Therapeutics Inc |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment.
|
US10590169B2
(en)
*
|
2015-12-09 |
2020-03-17 |
Virogin Biotech Canada Ltd |
Compositions and methods for inhibiting CD279 interactions
|
US11091556B2
(en)
|
2015-12-18 |
2021-08-17 |
Intervet Inc. |
Caninized human antibodies to human IL-4R alpha
|
JP6911031B2
(en)
|
2015-12-22 |
2021-07-28 |
インサイト・コーポレイションIncyte Corporation |
Heterocyclic compounds as immunomodulators
|
US10052315B2
(en)
|
2016-01-08 |
2018-08-21 |
Celgene Corporation |
Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
|
SI3399978T1
(en)
|
2016-01-08 |
2021-01-29 |
Celgene Corporation |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
ES2959267T3
(en)
|
2016-01-08 |
2024-02-22 |
Celgene Corp |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide and their pharmaceutical compositions and uses
|
HUE052893T2
(en)
|
2016-01-13 |
2021-05-28 |
Acerta Pharma Bv |
Therapeutic combinations of an antifolate and a btk inhibitor
|
WO2017129790A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancer
|
US10822415B2
(en)
|
2016-01-28 |
2020-11-03 |
Inserm (Institut National De La Santéet De La Recherche Médicale) |
Methods for enhancing the potency of the immune checkpoint inhibitors
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
CN116813799A
(en)
|
2016-02-05 |
2023-09-29 |
奥里尼斯生物科学私人有限公司 |
CLEC9A binding agents and uses thereof
|
RU2018131123A
(en)
|
2016-02-17 |
2020-03-17 |
Новартис Аг |
ANTIBODIES TO TGF-BETA2
|
MX2018010295A
(en)
|
2016-02-26 |
2019-06-06 |
Inst Nat Sante Rech Med |
Antibodies having specificity for btla and uses thereof.
|
US20190284293A1
(en)
|
2016-03-04 |
2019-09-19 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CN107226842B
(en)
*
|
2016-03-24 |
2022-01-28 |
华东理工大学 |
PD-1 targeted polypeptide and application thereof
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
KR102370704B1
(en)
|
2016-04-07 |
2022-03-03 |
케모센트릭스, 인크. |
A method of reducing total tumor mass by administering a CCR1 antagonist in combination with a PD-1 inhibitor or a PD-L1 inhibitor
|
MA44723A
(en)
|
2016-04-18 |
2019-02-27 |
Celldex Therapeutics Inc |
HUMAN CD40 BINDING AGONIST ANTIBODIES AND THEIR USES
|
EP3454887B1
(en)
|
2016-05-13 |
2021-01-20 |
Orionis Biosciences BV |
Targeted mutant interferon-beta and uses thereof
|
WO2017194782A2
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Therapeutic targeting of non-cellular structures
|
SG11201810177VA
(en)
|
2016-05-19 |
2018-12-28 |
Bristol Myers Squibb Co |
Pet-imaging immunomodulators
|
WO2017202962A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
CA3025057A1
(en)
|
2016-05-25 |
2017-11-30 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating cancers
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
SG10202012828TA
(en)
|
2016-06-20 |
2021-01-28 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
CA3028718A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
US20190248893A1
(en)
|
2016-07-14 |
2019-08-15 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
US20230184784A1
(en)
*
|
2016-08-11 |
2023-06-15 |
The Council Of The Queensland Institute Of Medical Research |
Immune status biomarkers and uses therefor
|
WO2018029336A1
(en)
|
2016-08-12 |
2018-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
|
US11701357B2
(en)
|
2016-08-19 |
2023-07-18 |
Beigene Switzerland Gmbh |
Treatment of B cell cancers using a combination comprising Btk inhibitors
|
US10858390B2
(en)
*
|
2016-09-02 |
2020-12-08 |
Cem Corporation |
Use of excess carbodiimide for peptide synthesis at elevated temperatures
|
WO2018046738A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
WO2018046736A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
WO2018047143A1
(en)
*
|
2016-09-12 |
2018-03-15 |
Aurigene Discovery Technologies Limited |
Vista signaling pathway inhibitory compounds useful as immunomodulators
|
US10799555B2
(en)
|
2016-09-15 |
2020-10-13 |
Leidos, Inc. |
PD-1 peptide inhibitors
|
WO2018053218A1
(en)
|
2016-09-15 |
2018-03-22 |
Leidos, Inc. |
Pd-1 peptide inhibitors
|
US20200016177A1
(en)
|
2016-09-22 |
2020-01-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
|
JP6811857B2
(en)
|
2016-10-14 |
2021-01-13 |
プレシジョン バイオサイエンシズ,インク. |
Genetically engineered meganuclease specific for the recognition sequence of the hepatitis B virus genome
|
WO2018075447A1
(en)
|
2016-10-19 |
2018-04-26 |
The Trustees Of Columbia University In The City Of New York |
Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
|
US11084859B2
(en)
|
2016-10-24 |
2021-08-10 |
Orionis Biosciences BV |
Targeted mutant interferon-gamma and uses thereof
|
TWI788307B
(en)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
|
KR102526034B1
(en)
|
2016-11-07 |
2023-04-25 |
브리스톨-마이어스 스큅 컴퍼니 |
immunomodulator
|
US20190345500A1
(en)
|
2016-11-14 |
2019-11-14 |
|Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
US10308644B2
(en)
|
2016-12-22 |
2019-06-04 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
CA3047508A1
(en)
|
2016-12-23 |
2018-06-28 |
Virttu Biologics Limited |
Treatment of cancer
|
WO2018122249A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
|
WO2018122245A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
|
CA3049435A1
(en)
|
2017-01-09 |
2018-07-12 |
Scott Grindrod |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US10434095B2
(en)
|
2017-01-27 |
2019-10-08 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
EP3576765A4
(en)
|
2017-02-06 |
2020-12-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
CA3052523A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences Nv |
Targeted chimeric proteins and uses thereof
|
WO2018146128A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
WO2018146148A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for predicting the response to checkpoint blockade cancer immunotherapy
|
PL3579874T3
(en)
|
2017-02-10 |
2022-02-28 |
Novartis Ag |
1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
|
CN110337305A
(en)
|
2017-02-28 |
2019-10-15 |
赛诺菲 |
Therapeutic RNA
|
CA3056392A1
(en)
|
2017-03-15 |
2018-09-20 |
Amgen Inc. |
Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
|
ES2963635T3
(en)
*
|
2017-03-28 |
2024-04-01 |
Ohio State Innovation Foundation |
Human PD1 peptide vaccines and uses thereof
|
JOP20190203A1
(en)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
Anti-tigit antigen-binding proteins and methods of use thereof
|
EP3391907B8
(en)
|
2017-04-20 |
2020-03-04 |
iOmx Therapeutics AG |
Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
|
BR112019021880A2
(en)
|
2017-04-20 |
2020-06-02 |
Adc Therapeutics Sa |
COMBINATION THERAPY WITH ANTI-AXL-DRUG ANTIBODY CONJUGATE
|
MX2019012465A
(en)
|
2017-04-20 |
2020-07-27 |
Adc Therapeutics Sa |
Combination therapy with an anti-cd25 antibody-drug conjugate.
|
CN110621341A
(en)
|
2017-04-26 |
2019-12-27 |
百时美施贵宝公司 |
Antibody production method that minimizes disulfide bond reduction
|
AR111651A1
(en)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
|
CN110869392A
(en)
|
2017-05-16 |
2020-03-06 |
百时美施贵宝公司 |
Treatment of cancer with anti-GITR agonistic antibodies
|
EP3624837A1
(en)
|
2017-05-16 |
2020-03-25 |
Five Prime Therapeutics, Inc. |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
AR111760A1
(en)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
|
MX2019013132A
(en)
|
2017-05-25 |
2020-01-27 |
Bristol Myers Squibb Co |
Antibodies comprising modified heavy constant regions.
|
AR111960A1
(en)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
|
EP3630842A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
PL3631454T3
(en)
|
2017-05-30 |
2024-01-29 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
CN118356488A
(en)
|
2017-05-30 |
2024-07-19 |
百时美施贵宝公司 |
Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
|
JOP20190279A1
(en)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
Crystalline forms of 5-bromo-2,6-di(1 h-pyrazol-1-yl)pyrimidin-4-amine and new salts
|
BR112019026564A2
(en)
|
2017-06-14 |
2020-06-30 |
Adc Therapeutics Sa |
dosing regimens for administration of an anti-cd19 adc
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
JP2020524157A
(en)
|
2017-06-20 |
2020-08-13 |
アンスティテュート キュリー |
Inhibitors of SUV39H1 histone methyltransferase for use in cancer combination therapy
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
CN110785187B
(en)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
Antibody molecules against CD73 and uses thereof
|
US20190048072A1
(en)
|
2017-06-22 |
2019-02-14 |
Novartis Ag |
USE OF IL-1beta BINDING ANTIBODIES
|
IL271491B2
(en)
|
2017-06-22 |
2023-09-01 |
Celgene Corp |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
JP7206222B2
(en)
|
2017-06-23 |
2023-01-17 |
ブリストル-マイヤーズ スクイブ カンパニー |
Immunomodulators that act as antagonists of PD-1
|
CN111093700B
(en)
|
2017-06-27 |
2024-07-16 |
纽洛可科学有限公司 |
Use of anti-FAM 19A5 antibodies for the treatment of cancer
|
WO2019006007A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
LT3644999T
(en)
|
2017-06-30 |
2023-03-10 |
Celgene Corporation |
Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
|
JP7258009B2
(en)
|
2017-07-10 |
2023-04-14 |
セルジーン コーポレイション |
Antiproliferative compounds and methods of use thereof
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
WO2019020593A1
(en)
|
2017-07-25 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
EP4364741A3
(en)
|
2017-08-18 |
2024-07-03 |
Cothera Bioscience, Inc. |
Polymorphic form of tg02
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib
|
US20210060158A1
(en)
|
2017-09-19 |
2021-03-04 |
Institut Curie |
Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
Crystal forms of immunomodulators
|
US11492375B2
(en)
|
2017-10-03 |
2022-11-08 |
Bristol-Myers Squibb Company |
Cyclic peptide immunomodulators
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
AU2018348350B2
(en)
|
2017-10-11 |
2024-05-02 |
Aurigene Oncology Limited |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
BR112020008537A2
(en)
|
2017-11-03 |
2020-10-06 |
Aurigene Discovery Technologies Limited |
dual tim-3 and pd-1 pathway inhibitors
|
AU2018359967A1
(en)
|
2017-11-06 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CA3081675A1
(en)
|
2017-11-06 |
2019-05-09 |
Aurigene Discovery Technologies Limited |
Conjoint therapies for immunomodulation
|
US20200353050A1
(en)
|
2017-11-10 |
2020-11-12 |
Armo Biosciences, Inc. |
Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
|
EP3710053A1
(en)
|
2017-11-16 |
2020-09-23 |
Novartis AG |
Combination therapies
|
CA3083158A1
(en)
|
2017-11-24 |
2019-05-31 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and compositions for treating cancers
|
TW201925782A
(en)
|
2017-11-30 |
2019-07-01 |
瑞士商諾華公司 |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
TW201925241A
(en)
*
|
2017-11-30 |
2019-07-01 |
美商格里佛診斷方法股份有限公司 |
Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD-1 and PD-L1
|
AU2018392212B9
(en)
|
2017-12-20 |
2021-03-18 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
CA3084569A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
WO2019133747A1
(en)
|
2017-12-27 |
2019-07-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
CN112218651A
(en)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
Immunopotentiating RNA for combination with chimeric antigen receptor therapy
|
CN112004537A
(en)
|
2018-01-09 |
2020-11-27 |
穿梭药业公司 |
Selective histone deacetylase inhibitors for the treatment of human diseases
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
BR112020013144A2
(en)
|
2018-01-12 |
2020-12-08 |
Bristol-Myers Squibb Company |
COMBINATION THERAPY WITH ANTI-IL-8 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR CANCER TREATMENT
|
CA3096287A1
(en)
|
2018-01-22 |
2019-07-25 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
WO2019152979A1
(en)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
WO2019157124A1
(en)
|
2018-02-08 |
2019-08-15 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
CN111788204B
(en)
|
2018-02-26 |
2023-05-05 |
吉利德科学公司 |
Substituted pyrrolizine compounds as inhibitors of HBV replication
|
AU2019227607C1
(en)
|
2018-02-27 |
2023-07-20 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
|
CA3090620A1
(en)
|
2018-03-06 |
2019-09-12 |
Institut Curie |
Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
|
AU2019239747A1
(en)
|
2018-03-21 |
2020-10-08 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
TWI818007B
(en)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-cyclic dinucleotides
|
TW202005654A
(en)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2'2'-cyclic dinucleotides
|
TWI833744B
(en)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-cyclic dinucleotides
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
AU2019252795A1
(en)
|
2018-04-12 |
2020-10-29 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
US20210179602A1
(en)
|
2018-04-20 |
2021-06-17 |
Iomx Therapeutics Ag |
A 5-thiazolecarboxamide kinase inhibitor and uses thereof
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
BR112020022392A2
(en)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
solid forms of a fgfr inhibitor and processes for preparing them
|
JP2021523118A
(en)
|
2018-05-04 |
2021-09-02 |
インサイト・コーポレイションIncyte Corporation |
FGFR inhibitor salt
|
CA3100731A1
(en)
|
2018-05-18 |
2019-11-21 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
KR20210021996A
(en)
|
2018-05-23 |
2021-03-02 |
셀진 코포레이션 |
Antiproliferative compounds and bispecific antibodies against BCMA and CD3 for combination use
|
US10969381B2
(en)
|
2018-05-23 |
2021-04-06 |
Celgene Corporation |
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
|
US20220111065A1
(en)
|
2018-05-23 |
2022-04-14 |
Adc Therapeutics Sa |
Molecular adjuvant
|
AR126019A1
(en)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
WO2019245817A1
(en)
|
2018-06-19 |
2019-12-26 |
Armo Biosciences, Inc. |
Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
US11161850B2
(en)
|
2018-07-05 |
2021-11-02 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
KR20210030405A
(en)
|
2018-07-09 |
2021-03-17 |
파이브 프라임 테라퓨틱스, 인크. |
Antibodies that bind to ILT4
|
HUE063715T2
(en)
|
2018-07-10 |
2024-01-28 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
AR116109A1
(en)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
TW202011991A
(en)
|
2018-07-18 |
2020-04-01 |
美商建南德克公司 |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
AU2019306628A1
(en)
|
2018-07-20 |
2021-02-11 |
Surface Oncology, LLC |
Anti-CD112R compositions and methods
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
SG11202100693UA
(en)
|
2018-07-26 |
2021-02-25 |
Bristol Myers Squibb Co |
Lag-3 combination therapy for the treatment of cancer
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
WO2020030634A1
(en)
|
2018-08-06 |
2020-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers
|
TW202031273A
(en)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
JP7535500B2
(en)
|
2018-09-03 |
2024-08-16 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Carboxamide and Sulfonamide Derivatives Useful as TEAD Modulators
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
EP3852524B1
(en)
|
2018-09-20 |
2023-06-28 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
WO2020079581A1
(en)
|
2018-10-16 |
2020-04-23 |
Novartis Ag |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
WO2020079164A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
|
KR20210080437A
(en)
|
2018-10-19 |
2021-06-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Combination Therapy for Melanoma
|
EP3643713A1
(en)
|
2018-10-23 |
2020-04-29 |
iOmx Therapeutics AG |
Heterocyclic kinase inhibitors and uses thereof
|
MX2021005047A
(en)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences Inc |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors.
|
CA3116347A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
EP3880231A1
(en)
|
2018-11-16 |
2021-09-22 |
NeoImmuneTech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
AU2019383423B2
(en)
|
2018-11-21 |
2023-11-23 |
Mayo Foundation For Medical Education And Research |
Adenoviruses and methods for using adenoviruses
|
JP2022513653A
(en)
|
2018-11-28 |
2022-02-09 |
ブリストル-マイヤーズ スクイブ カンパニー |
Antibodies containing modified heavy chain constant regions
|
EP3890749A4
(en)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
KR20210106437A
(en)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
Dosage regimens and pharmaceutical combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
AU2019406840A1
(en)
|
2018-12-21 |
2021-06-03 |
Novartis Ag |
Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
CN113166762A
(en)
|
2018-12-21 |
2021-07-23 |
欧恩科斯欧公司 |
Novel conjugated nucleic acid molecules and uses thereof
|
US20220056123A1
(en)
|
2018-12-21 |
2022-02-24 |
Novartis Ag |
Use of il-1beta binding antibodies
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
EP3897854A2
(en)
|
2018-12-21 |
2021-10-27 |
Aim Immunotech Inc. |
Compositions and methods for cancer therapy
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
WO2020140012A1
(en)
|
2018-12-27 |
2020-07-02 |
Amgen Inc. |
Lyophilized virus formulations
|
JP2022517324A
(en)
|
2019-01-03 |
2022-03-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Methods and Pharmaceutical Compositions for Enhancing CD8-Positive T Cell-Dependent Immune Responses in Cancer-Stricken Subjects
|
WO2020146441A1
(en)
|
2019-01-09 |
2020-07-16 |
Celgene Corporation |
Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
|
CN113543786A
(en)
|
2019-01-09 |
2021-10-22 |
细胞基因公司 |
Antiproliferative compounds and second agents for the treatment of multiple myeloma
|
EA202191620A1
(en)
|
2019-01-09 |
2021-11-01 |
Селджин Корпорейшн |
SOLID FORMS CONTAINING (S) -4- (4- (4 - (((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-4-YL) OXY) METHYL) BENZYL) PIPERAZIN-1 -IL) -3-FLUOROBENZONITRILE AND ITS SALTS, AND THEIR COMPOSITIONS AND METHODS OF THEIR APPLICATION
|
EP3911678A1
(en)
|
2019-01-14 |
2021-11-24 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
TWI829857B
(en)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
|
CN113412262A
(en)
|
2019-02-12 |
2021-09-17 |
大日本住友制药肿瘤公司 |
Formulations comprising heterocyclic protein kinase inhibitors
|
CN113329792B
(en)
|
2019-02-15 |
2024-06-28 |
诺华股份有限公司 |
Substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
JP2022519772A
(en)
|
2019-02-15 |
2022-03-24 |
インサイト・コーポレイション |
Cyclin-dependent kinase 2 biomarker and its use
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
MX2021010458A
(en)
|
2019-03-05 |
2021-09-21 |
Amgen Inc |
Use of oncolytic viruses for the treatment of cancer.
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
EP3935066A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
CN113543851A
(en)
|
2019-03-07 |
2021-10-22 |
捷克共和国有机化学与生物化学研究所 |
2'3' -cyclic dinucleotides and their prodrugs
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
JP2022525149A
(en)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure
|
CA3133460A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
AU2020248002A1
(en)
|
2019-03-26 |
2021-10-21 |
The Regents Of The University Of Michigan |
Small molecule degraders of STAT3
|
TW202102543A
(en)
|
2019-03-29 |
2021-01-16 |
美商安進公司 |
Use of oncolytic viruses in the neoadjuvant therapy of cancer
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
US20220185831A1
(en)
|
2019-03-29 |
2022-06-16 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
TWI751517B
(en)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
Solid forms of a toll-like receptor modulator
|
TWI751516B
(en)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
Solid forms of a toll-like receptor modulator
|
AU2020258480A1
(en)
|
2019-04-19 |
2021-10-21 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
SG11202109196XA
(en)
*
|
2019-04-29 |
2021-09-29 |
Mayo Found Medical Education & Res |
Multivalent pd-l1 binding compounds for treating cancer
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
WO2020226633A1
(en)
|
2019-05-07 |
2020-11-12 |
Immunicom, Inc. |
Increasing responses to checkpoint inhibitors by extracorporeal apheresis
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
CN114222729A
(en)
|
2019-06-12 |
2022-03-22 |
范德比尔特大学 |
Amino acid transport inhibitors and uses thereof
|
EP3983377A1
(en)
|
2019-06-12 |
2022-04-20 |
Vanderbilt University |
Dibenzylamines as amino acid transport inhibitors
|
CA3138188A1
(en)
|
2019-07-02 |
2021-01-07 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
US11529350B2
(en)
|
2019-07-03 |
2022-12-20 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
MX2022000550A
(en)
|
2019-07-16 |
2022-02-10 |
Univ Michigan Regents |
Imidazopyrimidines as eed inhibitors and the use thereof.
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
CA3150681A1
(en)
|
2019-08-14 |
2021-02-18 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
CN114641337A
(en)
|
2019-08-27 |
2022-06-17 |
密歇根大学董事会 |
CEREBLON E3 ligase inhibitors
|
CN110669108A
(en)
*
|
2019-09-06 |
2020-01-10 |
中国药科大学 |
Polypeptide and application thereof
|
TW202124446A
(en)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
Combination therapies with entpd2 antibodies
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
AU2020350689A1
(en)
|
2019-09-19 |
2022-03-31 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
JP2022548775A
(en)
|
2019-09-19 |
2022-11-21 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Spirocyclic Androgen Receptor Proteolytic Agent
|
CN117843811A
(en)
|
2019-09-30 |
2024-04-09 |
吉利德科学公司 |
HBV vaccine and method of treating HBV
|
AU2020364007A1
(en)
|
2019-10-11 |
2022-04-28 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
BR112022007163A2
(en)
|
2019-10-14 |
2022-08-23 |
Incyte Corp |
BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
TW202128191A
(en)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3 inhibitors and uses thereof
|
KR20220103947A
(en)
|
2019-10-21 |
2022-07-25 |
노파르티스 아게 |
Combination Therapy with Venetoclax and TIM-3 Inhibitors
|
CN114829366A
(en)
|
2019-11-11 |
2022-07-29 |
因赛特公司 |
Salts and crystalline forms of PD-1/PD-L1 inhibitors
|
TW202130618A
(en)
|
2019-11-13 |
2021-08-16 |
美商建南德克公司 |
Therapeutic compounds and methods of use
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
US20230000864A1
(en)
|
2019-11-22 |
2023-01-05 |
Sumitomo Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
IL293001A
(en)
|
2019-12-04 |
2022-07-01 |
Incyte Corp |
Derivatives of an fgfr inhibitor
|
JP2023505258A
(en)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Tricyclic heterocycles as FGFR inhibitors
|
CN116057068A
(en)
|
2019-12-06 |
2023-05-02 |
精密生物科学公司 |
Optimized engineered meganucleases with specificity for recognition sequences in hepatitis b virus genomes
|
CA3165274A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
CN113348170B
(en)
|
2020-01-03 |
2023-12-22 |
上海翰森生物医药科技有限公司 |
Biphenyl derivative inhibitor, preparation method and application thereof
|
CN115279766A
(en)
|
2020-01-03 |
2022-11-01 |
因赛特公司 |
Combination therapy comprising A2A/A2B and PD-1/PD-L1 inhibitors
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
JP2023510393A
(en)
|
2020-01-17 |
2023-03-13 |
ノバルティス アーゲー |
A combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
IL295093A
(en)
|
2020-01-30 |
2022-09-01 |
Ona Therapeutics S L |
Combination therapy for treatment of cancer and cancer metastasis
|
CA3164559A1
(en)
|
2020-01-31 |
2021-08-05 |
Lars Mueller |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
MX2022010860A
(en)
|
2020-03-06 |
2022-12-02 |
Incyte Corp |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors.
|
JP2023516724A
(en)
|
2020-03-06 |
2023-04-20 |
オーエヌエー セラピューティクス エセ.エレ. |
Anti-CD36 antibodies and their use to treat cancer
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
WO2021183318A2
(en)
|
2020-03-09 |
2021-09-16 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
WO2021188959A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
WO2021195481A1
(en)
|
2020-03-26 |
2021-09-30 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
IL297165A
(en)
|
2020-04-16 |
2022-12-01 |
Incyte Corp |
Fused tricyclic kras inhibitors
|
EP3901151A1
(en)
|
2020-04-21 |
2021-10-27 |
iOmx Therapeutics AG |
Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
|
EP4139440A1
(en)
|
2020-04-22 |
2023-03-01 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
WO2021219731A2
(en)
|
2020-04-28 |
2021-11-04 |
Iomx Therapeutics Ag |
Bicyclic kinase inhibitors and uses thereof
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
US20230173095A1
(en)
|
2020-05-29 |
2023-06-08 |
President And Fellows Of Harvard College |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
WO2021247789A1
(en)
|
2020-06-04 |
2021-12-09 |
Leidos, Inc. |
Immunomodulatory compounds
|
AR122644A1
(en)
|
2020-06-19 |
2022-09-28 |
Onxeo |
NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2021262969A1
(en)
|
2020-06-24 |
2021-12-30 |
The General Hospital Corporation |
Materials and methods of treating cancer
|
AU2021296876A1
(en)
|
2020-06-25 |
2023-02-02 |
Celgene Corporation |
Methods for treating cancer with combination therapies
|
WO2022002874A1
(en)
|
2020-06-30 |
2022-01-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
|
JP2023531305A
(en)
|
2020-06-30 |
2023-07-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
A method for predicting the risk of recurrence and/or death in patients with solid tumors after neoadjuvant therapy.
|
CA3182579A1
(en)
|
2020-07-07 |
2022-01-13 |
Ugur Sahin |
Therapeutic rna for hpv-positive cancer
|
CA3184460A1
(en)
|
2020-07-07 |
2022-01-13 |
Celgene Corporation |
Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the sam
|
WO2022011205A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
WO2022011204A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
KR20230050389A
(en)
|
2020-08-13 |
2023-04-14 |
브리스톨-마이어스 스큅 컴퍼니 |
Methods for Redirecting IL-2 to Target Cells of Interest
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
AU2021344422A1
(en)
|
2020-09-16 |
2023-05-04 |
Gordon J. Freeman |
Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
AU2021361844A1
(en)
|
2020-10-12 |
2023-06-15 |
Leidos, Inc. |
Immunomodulatory peptides
|
WO2022086957A1
(en)
|
2020-10-20 |
2022-04-28 |
Genentech, Inc. |
Peg-conjugated anti-mertk antibodies and methods of use
|
JP2023549678A
(en)
|
2020-10-28 |
2023-11-29 |
イケナ オンコロジー, インコーポレイテッド |
Combination of AHR inhibitors with PDx inhibitors or doxorubicin
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
US11760756B2
(en)
|
2020-11-06 |
2023-09-19 |
Incyte Corporation |
Crystalline form of a PD-1/PD-L1 inhibitor
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
MX2023005362A
(en)
|
2020-11-06 |
2023-06-22 |
Incyte Corp |
Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof.
|
MX2023004941A
(en)
|
2020-11-08 |
2023-07-12 |
Seagen Inc |
Combination-therapy antibody drug conjugate with immune cell inhibitor.
|
EP4255481A1
(en)
|
2020-12-02 |
2023-10-11 |
Genentech, Inc. |
Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
|
KR20220082558A
(en)
|
2020-12-10 |
2022-06-17 |
재단법인 의약바이오컨버젼스연구단 |
Novel fragmented cysteinyl-tRNA synthetase peptide with immune-enhancing activity and use thereof
|
TW202237119A
(en)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk-5 inhibitors and uses thereof
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
TW202245808A
(en)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
WO2022147092A1
(en)
|
2020-12-29 |
2022-07-07 |
Incyte Corporation |
Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
|
EP4274616A2
(en)
|
2021-01-11 |
2023-11-15 |
Synthekine, Inc. |
Compositions and methods related to receptor pairing
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
EP4292596A1
(en)
|
2021-02-10 |
2023-12-20 |
Curon Biopharmaceutical (Shanghai) Co., Limited |
Method and combination for treating tumors
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
US20240190874A1
(en)
|
2021-03-03 |
2024-06-13 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
WO2022187423A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Cereblon ligands
|
WO2022195551A1
(en)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
BR112023018950A2
(en)
|
2021-03-19 |
2024-02-27 |
Icahn School Med Mount Sinai |
COMPOUND, NANOBIOLOGICAL AND PHARMACEUTICAL COMPOSITIONS, METHODS FOR TREATING A CELL PROLIFERATION DISORDER, FOR TREATING SEPSIS AND FOR ACTIVATING A NOD2 RECEPTOR, PROCESS FOR MANUFACTURING A NANOBIOLOGICAL COMPOSITION AND KIT
|
TW202304506A
(en)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
TW202304979A
(en)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
|
IL307556A
(en)
|
2021-04-09 |
2023-12-01 |
Seagen Inc |
Methods of treating cancer with anti-tigit antibodies
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
US12037346B2
(en)
|
2021-04-13 |
2024-07-16 |
Nuvalent, Inc. |
Amino-substituted heteroaryls for treating cancers with EGFR mutations
|
EP4326333A1
(en)
|
2021-04-20 |
2024-02-28 |
Seagen Inc. |
Modulation of antibody-dependent cellular cytotoxicity
|
EP4330436A1
(en)
|
2021-04-30 |
2024-03-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
JP2024518558A
(en)
|
2021-05-13 |
2024-05-01 |
ギリアード サイエンシーズ, インコーポレイテッド |
Combination of TLR8 Modulating Compounds with Anti-HBV siRNA Therapeutics
|
AR125874A1
(en)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
COMBINATION THERAPIES
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
JP2024522189A
(en)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Tricyclic Heterocycles as FGFR Inhibitors
|
JP2024521947A
(en)
|
2021-06-11 |
2024-06-04 |
ギリアード サイエンシーズ, インコーポレイテッド |
Combination of MCL-1 inhibitors with antibody drug conjugates
|
TW202315637A
(en)
|
2021-06-11 |
2023-04-16 |
美商基利科學股份有限公司 |
Combination mcl-1 inhibitors with anti-cancer agents
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
IL309378A
(en)
|
2021-06-23 |
2024-02-01 |
Gilead Sciences Inc |
Diacylglyercol kinase modulating compounds
|
EP4359411A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
JP2024522698A
(en)
|
2021-06-23 |
2024-06-21 |
ギリアード サイエンシーズ, インコーポレイテッド |
Diacylglycerol kinase modulating compounds
|
KR20240005901A
(en)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
Diacylglycerol Kinase Modulating Compounds
|
EP4363449A2
(en)
|
2021-07-02 |
2024-05-08 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
CR20240059A
(en)
|
2021-07-07 |
2024-03-21 |
Incyte Corp |
Tricyclic compounds as inhibitors of kras
|
AU2022312698A1
(en)
|
2021-07-13 |
2024-01-25 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
EP4370515A1
(en)
|
2021-07-14 |
2024-05-22 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
MX2024001214A
(en)
|
2021-07-28 |
2024-02-12 |
Hoffmann La Roche |
Methods and compositions for treating cancer.
|
EP4377350A2
(en)
|
2021-07-28 |
2024-06-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
AU2022320051A1
(en)
|
2021-07-30 |
2024-01-25 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
WO2023034229A1
(en)
*
|
2021-08-30 |
2023-03-09 |
The Regents Of The University Of California |
Immune checkpoint targeting therapeutic nanoparticles
|
EP4396187A1
(en)
|
2021-08-31 |
2024-07-10 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
TW202321308A
(en)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
EP4408536A1
(en)
|
2021-10-01 |
2024-08-07 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
EP4413040A1
(en)
|
2021-10-06 |
2024-08-14 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination
|
TW202333802A
(en)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
Therapeutic rna for lung cancer
|
US11939328B2
(en)
|
2021-10-14 |
2024-03-26 |
Incyte Corporation |
Quinoline compounds as inhibitors of KRAS
|
KR20240099331A
(en)
|
2021-10-28 |
2024-06-28 |
라이엘 이뮤노파마, 인크. |
Method for cultivating immune cells
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
KR20240103007A
(en)
|
2021-11-12 |
2024-07-03 |
노파르티스 아게 |
Combination therapy for lung cancer treatment
|
CA3239205A1
(en)
|
2021-11-22 |
2023-05-25 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
TW202332429A
(en)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
Therapeutic compounds and methods of use
|
TW202329937A
(en)
|
2021-12-03 |
2023-08-01 |
美商英塞特公司 |
Bicyclic amine cdk12 inhibitors
|
US20230183251A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
WO2023111203A1
(en)
|
2021-12-16 |
2023-06-22 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
IL313735A
(en)
|
2021-12-22 |
2024-08-01 |
Incyte Corp |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
WO2023172921A1
(en)
|
2022-03-07 |
2023-09-14 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
CN114805499A
(en)
*
|
2022-04-24 |
2022-07-29 |
中南大学湘雅医院 |
PET molecular probe with PD-L1 pathway as target spot and application thereof
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202413412A
(en)
|
2022-05-12 |
2024-04-01 |
丹麥商珍美寶股份有限公司 |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
TW202402279A
(en)
|
2022-06-08 |
2024-01-16 |
美商英塞特公司 |
Tricyclic triazolo compounds as dgk inhibitors
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
TW202417042A
(en)
|
2022-07-13 |
2024-05-01 |
美商建南德克公司 |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202413433A
(en)
|
2022-07-19 |
2024-04-01 |
美商建南德克公司 |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024069009A1
(en)
|
2022-09-30 |
2024-04-04 |
Alentis Therapeutics Ag |
Treatment of drug-resistant hepatocellular carcinoma
|
WO2024077166A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
WO2024084013A1
(en)
|
2022-10-20 |
2024-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination therapy for the treatment of cancer
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
US20240217989A1
(en)
|
2022-11-18 |
2024-07-04 |
Incyte Corporation |
Heteroaryl Fluoroalkenes As DGK Inhibitors
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
WO2024111633A1
(en)
*
|
2022-11-24 |
2024-05-30 |
国立大学法人徳島大学 |
Production of antibodies against protein
|
WO2024115725A1
(en)
|
2022-12-01 |
2024-06-06 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
WO2024116140A1
(en)
|
2022-12-01 |
2024-06-06 |
Medimmune Limited |
Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
|
WO2024126457A1
(en)
|
2022-12-14 |
2024-06-20 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
WO2024137589A2
(en)
|
2022-12-20 |
2024-06-27 |
Genentech, Inc. |
Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
|
WO2024150177A1
(en)
|
2023-01-11 |
2024-07-18 |
Advesya |
Treatment methods for solid tumors
|
WO2024151346A1
(en)
|
2023-01-12 |
2024-07-18 |
Incyte Corporation |
Heteroaryl fluoroalkenes as dgk inhibitors
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|